RxDoctor Payments Data

Joseph Biber, MD

Ophthalmology · Charlotte, NCNPI 1457440620

Payments from drug & device makers

$7,832in general payments, 2019–2025

Across 276 payments — averaging $28.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eyevance Pharmaceuticals LLC$2K
  • Alcon$1K
  • AbbVie$827
  • US Retina LLC$814
  • Tarsus Pharmaceuticals, Inc.$578
  • Oyster Point Pharma, Inc.$489
  • plus $3K from 17 others

What the payments were for

  • Consulting fees$1,25016%
  • Food & beverage$5,65172%
  • Education$1182%
  • Ownership interest$81410%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,832 in reported general payments places this provider in the 80th percentile of 588 ophthalmology providers in North Carolina.

See all ophthalmology providers in North Carolina

Medicare billing

Part B allowed, 2024
$550,287
Medicare patients
957
Services billed
2,864

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine187$231,835
XiidraLifitegrast25$36,155
Prednisolone Acetate746$31,088
Fluorometholone348$23,266
Cyclosporine29$16,213
ProlensaBromfenac Sodium42$14,765
MieboPerfluorohexyloctane/Pf12$13,173
LotemaxLoteprednol Etabonate28$11,202
LumiganBimatoprost12$8,293
Loteprednol Etabonate66$8,125
Lotemax SmLoteprednol Etabonate21$5,941
Diclofenac Sodium164$2,647
Latanoprost186$2,565
Ofloxacin218$2,388
MoxifloxacinMoxifloxacin Hcl75$1,877

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$827$240,128199 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$104$49,32837 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax, Loteprednol Etabonate, Lotemax Sm$192$40,032157 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 588 ophthalmology providers in North Carolina.

Other ophthalmology in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →